一分钟看懂
这是一项关于非小细胞肺癌的II 期研究，登记的药物或干预包括Sutetinib Maleate Capsule，当前状态为招募中。登记地点显示中国蚌埠、北京、重庆、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Sutetinib Maleate Capsule · II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Bengbu Medical College · 蚌埠
- Cancer Hospital Chinese Academy of Medical Sciences · 北京
- Beijing Cancer Hospital · 北京
- Peking Union Medical College Hospital · 北京
- Beijing Chest Hospital · 北京
- The Affiliated Cancer Hospital of Chongqin University · 重庆
- The First Affiliated Hospital of Guangzhou Medical University · 广州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Henan Cancer Hospital · 郑州
- The First Affiliated Hospital of Zhengzhou University · 郑州
- Wuhan Union Hospital of China · 武汉
- Hunan Cancer Hospital · 长沙
- Jiangsu Province Hospital · 南京
- Jilin Cancer Hospital · 长春
- The First Affiliated Hospital of China Medical University · 沈阳
- Linyi Cancer Hospital · 临沂
- Shanghai Chest Hospital · 上海
- Shanghai Pulmonary Hospital · 上海
- Sichuan Cancer Hospital · 成都
- Zhejiang Cancer Hospital · 杭州
公开的入选条件
- 1. Age 18 years old and above, male or female.
- 2. Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC patients with ≤ 1 prior line of chemotherapy.
- 3. Confirmation that the tumor harbors a non-resistant uncommon EGFR mutation (tumor tissue biopsy), including one or more of L861Q, G719X and S768I mutations, excluding any other EGFR sensitive mutations and/or oncogenes..
- 4. At least one measurable lesion.
- 5. ECOG score of 0, 1, or 2.
- 6. A minimum life expectancy of \> 3 months.
- 7. Adequate bone marrow reserve, hepatic, renal and coagulation function.
- 8. Willingness of all subjects of childbearing potential to use acceptable methods of birth control.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05168566；登记信息更新于 2026-04-28。